Home » Judge Dismisses Teva API Patent Challenge Against Mylan, Sandoz
Judge Dismisses Teva API Patent Challenge Against Mylan, Sandoz
A district court judge granted motions to dismiss filed by Mylan and Sandoz after the companies agreed to abstain from using a method of measuring the active pharmaceutical ingredient (API) for multiple sclerosis drug Copaxone that Teva had challenged infringed on four of its patents.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May